Results for: CERO

CERo Therapeutics Holdings, Inc. (CERO) stock surged over 150% on Monday after the company presented preclinical data showing its lead compound, CER-1236, effectively kills ovarian cancer cells in preclinical models without causing toxicity. The positive results, coupled with the potential for orphan drug designation, have ignited investor enthusiasm.

An EA Japan executive has questioned the CERO ratings board’s consistency in Japan after Stellar Blade received an “uncensored” rating with dismemberment and gore, while EA’s Dead Space remake was refused a rating for similar content.